Advances in Gene Therapy: Facing Challenges and Adapting for the Future

3:30 PM - 4:25 PM (EST), Monday, February 10, 2020 ・ Lyceum Complex
Fewer than 20 gene therapies have so far been approved in the global market. With more than 750 under development, our future invites us to reap promising benefits as the field forges on, further substantiating this exciting new modality. Despite all the clinical progress, several challenges remain: almost all gene therapies approved and currently under development cluster in narrow indications for rare diseases, reaching relatively small patient populations; manufacturing continues to be costly; and high reimbursement amounts concern healthcare payers and patients. Hear from leaders in this field as they share their lessons learned and thoughts on the path forward to ensure gene therapies expand their reach to treat more patients on the road to cures.
Moderator
photo
Managing Director, Research (Biotechnology)
BTIG
Speakers
photo
Chief Executive Officer and Director
Orgenesis
photo
Senior Director of Global Gene Therapy Business
Pfizer Inc.
photo
Chief Business Officer
Prevail Therapeutics
photo
Vice President, External Innovation
Eli Lilly and Company